Skip to main content

Table 2 Baseline and final characteristics (per-protocol analysis)

From: Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry

Characteristics Whole sample Responders Non-responders Withdrew p
Mean/n/% SD Median IQR Mean/n/% SD Median IQR Mean/n/% SD Median IQR Mean/n/% SD Median IQR
General
 n (male/female) 279 (118/161)     161 (65/96)     48 (24/24)     70 (29/41)     0.488
 Age (year) 53.79 12.48 53.00 20.00 52.96 11.35 52.00 17.00 54.06 12.18 53.50 18.50 55.51 14.96 55.00 24.00 0.274
 Weight (kg) 78.42 17.40 78.00 25.00 78.24 17.36 75.00 25.00 81.52 18.19 80.00 21.00 76.69 16.91 78.50 25 0.452
 Total IgE (IU/ml) 355.47 325.88 244.00 366.00 349.52 311.55 225.00 386.00 399.44 317.69 319.50 352.00 339.00 363.78 207.50 361.00 0.186
 Omalizumab dose (mg/month) 472.04 250.36 450.00 300.00 469.10 246.94 300.00 300.00 509.38 299.58 450.00 375.00 453.21 220.59 300.00 300.00 0.772
Baseline
 FeNO (ppb) 51.38 46.31 38.00 52.00 51.01 48.52 38.00 51.00 46.80 33.53 38.00 50.00 55.81 48.76 44.00 56.00 0.877
 ACT (points) 12.34 4.10 12.00 6.00 12.55 3.86 12.00 6.00 10.64 4.04 10.00 5.00 13.03 4.42 12.00 7.00 0.005
 FEV1 (%pred) 64.45 18.17 66.00 24.00 63.58 18.20 65.00 24.00 65.81 16.80 66.50 22.50 65.51 19.11 67.50 19.00 0.660
 Severe exacerbations (n/year) 2.55 3.80 2.00 2.00 2.78 4.55 2.00 2.00 2.88 2.51 2.00 2.00 1.80 2.20 1.00 2.00 0.007
 Systemic corticosteroids (n/%) 201/72,0%     119/73,9%     40/83,3%     42/60,0%     0.015
 Prednisone (mg/day) 13.84 14.19 10.00 15.00 13.76 16.03 8.00 15.00 15.38 14.17 10.00 15.00 12.62 6.99 10.00 11.00 0.387
Final
 FeNO (ppb) 40.82 46.97 26.00 29.00 35.19 36.62 24.00 27.00 43.61 40.70 34.00 31.00 52.72 67.56 32.00 38.00 0.158
 ACT (points) 17.45 5.14 18.00 8.00 18.36 4.74 19.00 7.00 13.45 5.22 12.50 9.00 18.03 4.78 18.00 8.00 < 0.001
 FEV1 (%pred) 72.14 21.90 73.00 29.00 72.16 22.12 71.00 29.00 69.23 17.96 66.00 24.00 74.06 23.81 76.50 31.00 0.278
 Severe exacerbations (n/year) 1.03 2.64 0.00 1.00 0.94 2.59 0.00 1.00 1.81 3.88 1.00 2.00 0.70 1.37 0.00 1.00 0.022
 Systemic corticosteroids (n/%) 121/43,4%     68/42,2%     27/56,3%     26/37,1%     0.109
Prednisone (mg/day) 10.40 12.63 5.00 6.00 9.07 11.41 5.00 18.00 16.78 18.06 10.00 15.00 7.23 4.19 8.50 5.00 0.008
  1. Analysis: Kruskal–Wallis test, Chi-square test